Teva ups R&D investment in CureTech on positive PhII lymphoma study
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has decided to invest an additional $19 million in the Israeli biotech CureTech following the successful completion of a Phase II lymphoma study the anti-PD-1 monoclonal antibody, CT-011, their partnered drug for patients with diffuse large B cell lymphoma (DLBCL).